... showed significant lung function improvement two weeks after first dose that was sustained over 52 weeks Paris and Tarrytown, NY - May 21, 2018 -The New England Journal of Medicine (NEJM) today published detailed results from two Phase 3 trials for ...
http://www.globenewswire.com/news-release/2018/05/21/1509572/0/en/Sanofi-New-England-Journal-of-Medicine-publishes-two-positive-Phase-3-trials-showing-Dupixent-dupilumab-improved-moderate-to-severe-asthma.html
No comments:
Post a Comment